Selected publications
-
Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials.
Leukemia and Lymphoma.
2017
Academic Article
GET IT
Times cited: 4 -
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: Interim results from a phase 3, randomised, double-blind, placebo-controlled trial.
The Lancet Oncology.
2017
Academic Article
GET IT
Times cited: 87 -
Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.
Cancer Medicine.
2017
Academic Article
GET IT
Times cited: 8 -
Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial.
Journal of Hematology and Oncology.
2016
Academic Article
GET IT
Times cited: 15 -
The european hematology association roadmap for european hematology research: A consensus document.
Haematologica.
2016
Academic Article
GET IT
Times cited: 27 -
Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma.
Hematological Oncology.
2016
Information Resource
GET IT
Times cited: 8 -
Pancreatitis in patients treated with brentuximab vedotin: A previously unrecognized serious adverse event.
Blood.
2014
Information Resource
GET IT
Times cited: 31 -
Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: Pivotal study update demonstrates durable responses.
Journal of Hematology and Oncology.
2014
Academic Article
GET IT
Times cited: 101 -
Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: A subgroup efficacy analysis from the PROPEL study.
Clinical Lymphoma, Myeloma and Leukemia.
2012
Academic Article
GET IT
Times cited: 31 -
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.
Journal of Clinical Oncology.
2012
Academic Article
GET IT
Times cited: 348 -
Current treatment of peripheral T-cell lymphoma.
Clinical Advances in Hematology and Oncology.
2011
Review
GET IT
Times cited: 1 -
Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the group C protocol mechanism of the national cancer institute: A report of 979 patients.
Journal of Clinical Oncology.
1998
Academic Article
GET IT
Times cited: 135